APA (7th ed.) Citation

Lin, H., Hou, P., Huang, H., Desai, A., & Jahanzeb, M. (2018). PCN24 - Duration of Treatment and Economic Burden in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Receiving Second-Line Alk Inhibitors. Value in Health, 21, S17. https://doi.org/10.1016/j.jval.2018.04.102

Chicago Style (17th ed.) Citation

Lin, HM, P. Hou, H. Huang, A. Desai, and M. Jahanzeb. "PCN24 - Duration of Treatment and Economic Burden in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Receiving Second-Line Alk Inhibitors." Value in Health 21 (2018): S17. https://doi.org/10.1016/j.jval.2018.04.102.

MLA (9th ed.) Citation

Lin, HM, et al. "PCN24 - Duration of Treatment and Economic Burden in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Receiving Second-Line Alk Inhibitors." Value in Health, vol. 21, 2018, p. S17, https://doi.org/10.1016/j.jval.2018.04.102.